Regenxbio Inc
Follow $RGNX
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $RGNX by emailVeridion Score
BETALOW CONF · 5 of 6 factors measuredHighest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is RGNX moving today?
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
RGNX overview
Related filings and maps
Congress activity in RGNX
No receipt-qualified Congressional disclosure is present for RGNX in the cached public ledger.
RGNX contract awards, year to date.
Public federal awards linked to this ticker.
RGNX lobbying filings, year to date.
Registered lobbying filings matched to Regenxbio Inc.
THEGROUP DC, LLC
DLA PIPER LLP (US)
LMH STRATEGIC SOLUTIONS